ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ドロキシドパ

Droxidopa

HCID 92974
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
23651-95-8
標準SMILES
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
InChIKey
QXWYKJLNLSIPIN-JGVFFNPUSA-N
分子式
C9H11NO5
平均分子量
213.19 g/mol
単同位体質量
213.06372245

概要

Droxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension. It has a role as an antihypertensive agent, a prodrug and a vasoconstrictor agent. It is a L-tyrosine derivative and a member of catechols.

名称と識別子

優先名称
Droxidopa
IUPAC
(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
現地名
ドロキシドパ
英語名
DROXIDOPA
分子式
C9H11NO5
分子量
213.19

名称と別名

droxidopa23651-95-8L-DOPSDOPS(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acidNortherathreo-DopaserineL-threo-DOPSL-ThreodopsL-dihydroxyphenylserinedroxidopumSM 5688
名称をさらに表示
(2S,3R)-2-アミノ-3-ヒドロキシ-3-(3,4-ジヒドロキシフェニル)プロパン酸ドロキシドパ(2S,3R)-2-アミノ-3-(3,4-ジヒドロキシフェニル)-3-ヒドロキシプロピオン酸L-threo-3,4-ジヒドロキシフェニルセリンドロキシドーパドプス(3R)-3-(3,4-ジヒドロキシフェニル)-L-セリン(2S,3R)-2-アミノ-3-ヒドロキシ-3-(3,4-ジヒドロキシフェニル)プロピオン酸(βR)-β,3-ジヒドロキシ-L-チロシン[βR,(-)]-β,3-ジヒドロキシ-L-チロシン(2S,3R)-3-(3,4-ジヒドロキシフェニル)-3-ヒドロキシ-2-アミノプロピオン酸L-THREO-ドロキシドーパドロキシドパ (JP17)L-threo-3,4-DihydroxyphenylserineDroxidopa (JAN)roxidopaDroxydopaDroxidopa>Droxidopa-13C6
L-threo-dihydroxyphenylserineL-Tyrosine, beta,3-dihydroxy-, threo-CHEBI:31524J7A92W69L7DTXSID6046422threo DOPSthreo-DOPS(-)-(2S,3R)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-3-HYDROXYPROPANOIC ACID

物性

構造計算による物性

XLogP
-3.2
極性表面積
124 Ų
水素結合供与体数
5
水素結合受容体数
6
回転可能結合数
3
重原子数
15
形式電荷
0
複雑度
235

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
232 · 232-235° (dec); mp 229-232° (dec) (Ohashi)
比旋光度
20 · D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl)
沸点
549.8 · 549.8±50.0 °C(Predicted)
比重(密度)
1.608 · 1.608±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C
溶解性
3 mg/mL以上 · DMSO:3mg/mL以上
外見
粉
酸解離定数(Pka)
2.09 · 2.09±0.24(Predicted)
色
白から黄褐色
Merck
14 · 14,3457
安定性
吸湿性
InChI
InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/s3
InChIKey
QXWYKJLNLSIPIN-WWXSATIUNA-N

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

危険有害性情報

Hazard Classes and Categories · 2 件

Skin Irrit. 2 (100%)

Skin Irrit. 2 (100%)

毒性情報

Hepatotoxicity · 1 件

Liver test abnormalities have not been reported in patients taking droxidopa, but the agent has had limited clinical use. There were no episodes of clinically apparent liver injury reported in the preregistration trials of droxidopa, and since its approval there have been no published reports of droxidopa hepatotoxicity. Thus, liver injury from droxidopa is likely to be rare, if it occurs at all.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Droxidopa

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

安全データ

wgk
3
rtecs
VT9626010
hs_code
29225090

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 件

Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.

Mechanism of Action · 1 件

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.

Biological Half-Life2-3 hours.
Metabolism/MetabolitesDroxidopa is metabolized by aromatic L-amino acid decarboxylase.
FDA Pharmacological Classification · 6 件

J7A92W69L7

DROXIDOPA

Chemical Structure [CS] - Catecholamines

Physiologic Effects [PE] - Increased Blood Pressure

The physiologic effect of droxidopa is by means of Increased Blood Pressure.

DROXIDOPA

MeSH Pharmacological ClassificationAgents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Absorption, Distribution and Excretion · 2 件

Oral bioavailability is 90%.

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.

関連反応

6 件
反応記録を作成
HRID 343999 の反応式
HRID 343999生成物として
HRID 344000 の反応式
HRID 344000生成物として
HRID 408057 の反応式
HRID 408057生成物として
HRID 1599185 の反応式
HRID 1599185生成物として
HRID 1599186 の反応式
HRID 1599186生成物として
HRID 1762768 の反応式
HRID 1762768反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
23651-95-8、3916-18-5
PubChem CID
92974
DTXSID
DTXSID201017236
ChEMBL
CHEMBL2103827
ChEBI
CHEBI:31524
UNII
24A0V01WKS、J7A92W69L7
EC Number
223-480-5、688-528-3
Nikkaji
J22.085J
SMILES
[C@H](C1C=CC(O)=C(O)C=1)(O)[C@H](N)C(=O)O |&1:0,10,r|
CAS データベース
23651 · 23651-95-8

化学的性質

化学的特性Off-White Solid

risk_code
36/37/38
hazard_code
Xi
safety_code
26
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
ストレージクラス
11 - Combustible Solids
応用分野 · 5 件

用途ノルアドレナリン前駆体物質 です。芳香族L-アミノ酸脱炭酸酵素により、 ノルアドレナリンに変換されます。

用途ノルアドレナリン前駆体物質 です。芳香族L- アミノ酸脱炭酸酵素により、 ノルアドレナリンに変換されます。

説明Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.

使用The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.

一般的な説明L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.

補足説明

定義ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension